港股异动 | 美瑞健康国际续涨逾8% 拟收购一雾化产品企业8.307%股权
格隆汇9月5日丨美瑞健康国际(2327.HK)继昨日上涨6.67%后,于今日至现价0.52港元再度上涨8.33%,暂成交892.2万港元,最新总市值22.2亿港元。公司于昨日签订了股权转让协议,向一位自然人收购深圳龙舞的8.3077%股权(增资协议完成对深圳龙舞的6%增资后,该股权将被稀释到7.809231%),收购代价1080.29万元人民币。收购完成后,集团持有深圳龙舞约13.809231%的股权。深圳龙舞是一家旨在中国市场拓展雾化产品的创新性公司。公司董事认为中国雾化产品市场快速增长,市场规模非常大,公司通过入股深圳龙舞以参与在中国销售、推广雾化产品,将为集团带来新的增长点。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.